Efficacy and safety of antiintegrin antibody for inflammatory bowel disease a systematic review and meta-analysis

Medicine (United States)

Volumn 94, Issue 10, 2015, Pages

  Lin, Lianjie ^a   Liu, Xiang ^a   Wang, Dongxu ^a   Zheng, Changqing ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; NATALIZUMAB; VEDOLIZUMAB; ALPHA4 INTEGRIN; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY; RHUMAB BETA7;

CROHN DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FREQUENCY; HEADACHE; HUMAN; INFECTION; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHINOPHARYNGITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS; COLITIS, ULCERATIVE;

ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; INTEGRIN ALPHA4; TREATMENT OUTCOME;

EID: 84929026495     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000556     Document Type: Review

References (31)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.
2. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365: 1713-1725.
3. Mosli MH, Feagan BG. Vedolizumab for Crohn's disease. Expert Opin Biol Ther. 2013;13:455-463.
4. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657.
5. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factoralpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39:660-671.
6. Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-a therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:447-458.
7. Gilroy L, Allen PB. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? Clin Exp Gastroenterol. 2014;7:163-172.
8. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864-875.
9. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65-W94.
10. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998;51:1235-1241.
11. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711-721.
12. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6:1370-1377.
13. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672-1683.
14. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353:1912-1925.
15. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24-32.
16. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebocontrolled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001;121:268-274.
17. Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase I study of etrolizumab (rhuMAb (7) in moderate to severe ulcerative colitis. Gut. 2013;62:1122-1130.
18. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
19. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 doseranging study. Inflamm Bowel Dis. 2012;18:1470-1479.
20. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352:2499-2507.
21. Salmi M, Jalkanen S. Lymphocyte homing to the gut: attraction, adhesion, and commitment. Immunol Rev. 2005;206:100-113.
22. Engelhardt B, Briskin MJ. Therapeutic targeting of alpha 4-integrins in chronic inflammatory diseases: tipping the scales of risk towards benefit? Eur J Immunol. 2005;35:2268-2273.
23. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348:68-72.
24. Bamias G, Clark DJ, Rivera-Nieves J. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease. Curr Drug Targets. 2013;14:1490-1500.
25. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumabassociated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870-1880.
26. Behm BW, Bickston SJ. Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2009;1:CD007571.
27. MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2007;1:CD006097.
28. Lv R, Qiao W, Wu Z, et al. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One. 2014;9:e86692.
29. Fellermann K. Adverse events of tumor necrosis factor inhibitors. Dig Dis. 2013;31:374-378.
30. Patel V, Wang Y, MacDonald JK, et al. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2014;8:CD006884.
31. Chande N, Wang Y, MacDonald JK, et al. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014;8:CD006618.